Latest Triple-negative breast cancer Stories
The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers.
Regular use of low-dose aspirin may prevent the progression of breast cancer.
Triple-negative breast cancers are more biologically diverse than previously believed and classification should be expanded to reflect this heterogeneity
An anti-copper drug compound that disables the ability of bone marrow cells from setting up a "home" in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in one of the most difficult-to-treat forms of cancer -- high-risk triple-negative breast cancer.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors.